These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15816224)

  • 1. Strategies and impacts of new drug introduction: hemophilia treatment.
    Guirguis HS; Rogoff EG
    J Health Care Finance; 2004; 31(1):1-12. PubMed ID: 15816224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia.
    Rogoff EG; Guirguis HS; Lipton RA; Seremetis SV; DiMichele DM; Agnew GM; Karpatkin M; Barish RJ; Jones RL; Bianco C; Knothe BD; Lee MS
    Thromb Haemost; 2002 Oct; 88(4):545-53. PubMed ID: 12362223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the effect of pharmaceutical firm drug announcements on stock option pricing.
    Younis MM; Younies H; Kisa A; Hartmann M; Hussain AA; Al-Amro A
    J Health Care Finance; 2009; 35(3):35-43. PubMed ID: 19891206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generics market in Greece: the pharmaceutical industry's beliefs.
    Geitona M; Zavras D; Hatzikou M; Kyriopoulos J
    Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs and benefits of regulations for reimbursement of new drugs.
    Lundkvist J; Jönsson B; Rehnberg C
    Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical policy in China.
    Sun Q; Santoro MA; Meng Q; Liu C; Eggleston K
    Health Aff (Millwood); 2008; 27(4):1042-50. PubMed ID: 18607039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of privatization of the drug distribution system on drug prices in Malaysia.
    Babar ZD; Izham MI
    Public Health; 2009 Aug; 123(8):523-33. PubMed ID: 19665741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
    Jayadev A; Stiglitz J
    Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference pricing and firms' pricing strategies.
    Miraldo M
    J Health Econ; 2009 Jan; 28(1):176-97. PubMed ID: 19038465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription drug spending: contribution to health care spending and cost containment strategies.
    Rivers PA; Hall NG; Frimpong J
    J Health Care Finance; 2006; 32(3):8-19. PubMed ID: 18975728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug expenditure in Ireland 1997-2007.
    Barry M; Molloy D; Usher C; Tilson L
    Ir Med J; 2008; 101(10):299-302. PubMed ID: 19205138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should drug prices be negotiated under part D of Medicare? And if so, how?
    Frank RG; Newhouse JP
    Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.